COVID-19
Frequently Asked Questions – World Bank Group

Vaccinations: Access

When and where will I be able to get an approved COVID-19 vaccine? Will the World Bank Group be getting its own supply of vaccine for staff?

It is currently not possible for individual organizations to acquire Stringent Regulatory Authority (SRA) approved COVID-19 vaccine supplies, as all manufacturers’ production for the foreseeable future is allocated to national government administered programs and/or the WHO COVAX program. The WBG is monitoring this situation and will continue to explore opportunities for future vaccine procurement, shipping, and administration as they arise.

The foremost access option for staff and their families is through national programs in their locations or through the UN interagency vaccine program in locations where the UN has assessed national programs to be inadequate. Staff should monitor all available guidance from their national and local authorities for availability of nationally approved vaccines, as well as information on where they are positioned in the prioritization for vaccination. For more information on the vaccine development and approvals, this Coronavirus Vaccine Tracker is useful.

In the U.S., everyone aged 5 and older is eligible to get a COVID-19 vaccine to help protect against COVID-19. To find a vaccine location, visit Vaccines.gov or visit the local health departments of DC, Maryland, and Virginia for the latest information.

- District of Columbia Department of Health
- Maryland Department of Health
- Virginia Department of Health

Can I get the vaccine at the WBG on-site MedStar HQ clinic?

For information on signing up for the vaccine through MedStar, please visit this site.

Currently, the MedStar platform is accepting enrollments for staff, retirees, and their dependents residing anywhere in the DC Metro Area. You can fill out a form to be placed in the MedStar enrollment system.

Can I receive the vaccine if I am not a citizen of the country I live in? Will I have to pay for it?

In the U.S. vaccines are being administered regardless of citizenship status. Vaccines are being distributed free of charge as part of the federal distribution effort, but some providers may charge an administrative fee. However, there should be no additional out of pocket costs for the cost of the vaccine itself.
In Country Office locations, the UN system Resident Coordinators/agencies and programs, along with some Country Office Heads, are discussing inclusion of International Organizations in country specific national vaccination campaigns.

In some locations the Country Office has coordinated with Government and local health providers to facilitate vaccination within Country Office buildings. These COVID vaccination campaigns are part of the local government department of health response for key humanitarian and development partners like the WBG.

What if I work in a location where an approved vaccine is not available?

In certain circumstances where access is limited (e.g., locations where expatriate staff might be excluded from access, or where available vaccines have not been approved by WHO or Stringent Regulatory Authorities), the Bank Group has partnered with the United Nations system in a major interagency initiative to supply vaccines for the international development community. The first round of vaccine distributions has been completed, and UN Country Teams are coordinating with the UN Department of Operational Support for additional doses where these are needed.

Can I travel to get a COVID-19 vaccine? If I received my first dose of vaccine and then moved or traveled from the location where I received it, where can I get my second dose?

Countries are making their own determination on whether and when to approve COVID-19 vaccinations for children. Some countries have already moved forward with authorizing certain vaccines for younger age groups while others have not yet approved any vaccines for kids. Staff will need to follow national health authority guidance on this.

In the U.S., the FDA and CDC have authorized the use of a lower dose Pfizer mRNA vaccine in children aged 5 to 11. This lower dose vaccine is available to kids in that age group through community vaccination clinics and pediatricians offices. The European Medicines Agency (EMA) has also given approval for the lower dose Pfizer mRNA vaccine in children aged 5 to 11, and vaccine administration in various European countries is expected to begin in December.

A number of countries are vaccinating younger children with the Sinovac or Sinopharm vaccine. Several countries have also already authorized the standard/adult dose Pfizer mRNA vaccine for use in children aged 12 to 15 and the Moderna vaccine for kids aged 12 to 17 years. All other COVID-19 vaccines are authorized for people aged 18 and older. Pfizer currently has ongoing clinical trials to determining the safe dose for children younger than five.

Can children receive the vaccine?

Countries are making their own determination on whether and when to approve COVID-19 vaccinations for children. Some countries have already moved forward with authorizing certain vaccines for younger age groups while others have not yet approved any vaccines for kids. Staff will need to follow national health authority guidance on this.

In the U.S., the FDA and CDC have authorized the use of a lower dose Pfizer mRNA vaccine in children aged 5 to 11. This lower dose vaccine will be available to kids in that age group.
through community vaccination clinics and pediatricians’ offices. A number of countries are vaccinating younger children with the Sinovac or Sinopharm vaccine; and several countries have authorized the Pfizer mRNA vaccine for use in children aged 12 to 15 and the Moderna vaccine for kids aged 12 to 17 years. All other COVID-19 vaccines are authorized for people aged 18 and older. Pfizer and Moderna currently have ongoing clinical trials to determine the safe and effective dosage for children younger than five (younger than six for Moderna) and are expected to submit applications soon to the U.S. FDA for consideration.

Vaccinations: Safety and Efficacy

How do I know COVID-19 vaccines are safe and effective? If available, should I get a vaccine that has not been approved by the WHO or other Stringent Regulatory Authorities?

Vaccines approved by the WHO or a Stringent Regulatory Authority have completed phase 3 trials testing safety and efficacy in tens of thousands of people, and are approved based on their strong indications of both safety and efficacy. In addition, approved vaccines have now been administered to millions of people worldwide, and the U.S. CDC, European Medicines Agency (EMA), and other national health entities track safety among those who received the vaccine. The vaccines approved by WHO and a Stringent Regulatory Authority are overwhelmingly safe and effective at preventing symptomatic COVID-19 infections, hospitalization, and death. While some people may worry that the technologies used to develop COVID-19 vaccines are new (such as mRNA), these technologies have been in development for decades and are well studied by scientists. In the U.S., both the Pfizer and the Moderna mRNA vaccines have received full FDA approval (no longer only under emergency use authorization – EUA). Recalling that all COVID vaccines are administered and available via government/national authority/UN programs presently.

Given the health risks associated with COVID-19 and the stringent regulatory requirements for vaccine approval, HSD recommends that all who can safely receive an approved COVID-19 vaccine should do so, both for their own protection and to better protect those close to them. For more information on COVID-19 vaccine safety, visit the U.S. CDC’s website and the WHO’s FAQ on vaccine safety. Visit the CDC’s webpage on myths and facts about COVID-19 vaccines.

Staff in some countries have the opportunity to access vaccines which have not received WHO and/or Stringent Regulatory Authority approval. HSD is not in a position to recommend either for or against receiving these vaccines. The choice of vaccine is a personal one and should be guided by local public health authorities your healthcare provider. We can advise that any of the COVID-19 vaccines recommended by National Governments and Authorities are more effective in minimizing severe COVID-19 disease that not receiving any COVID-19 vaccine. An informed decision should be made in discussion with your health care provider.

Are the vaccines safe for those who are pregnant or breastfeeding?

The U.S. CDC recommends COVID-19 vaccination for pregnant and breastfeeding women. Pregnant women are at higher risk for severe illness from COVID-19 infection, and the vaccine will protect them as well as their unborn child. The evidence of safety of the COVID-19 vaccines in pregnant women has been growing, and the benefits of receiving the vaccine
outweigh any known or potential risks of vaccination during pregnancy. None of the vaccines are made with live virus, so there is no risk of passing on COVID-19 to the fetus through vaccination.

The [WHO also says that pregnant women can be vaccinated](https://www.who.int/news/item/20-july-2021) against COVID-19, in consultation with their healthcare provider, saying there is no specific safety concern based on what is known about the vaccines. For more on this from the WHO, see the "Science in 5" video.

The [CDC](https://www.cdc.gov) and WHO also recommend the vaccine for those who are breastfeeding. Some studies of breastfeeding mothers who were vaccinated have shown development of COVID-19 antibodies in the breastmilk, which may be protective for their babies.

**How effective are the vaccines, especially against COVID-19 variants? How long will a vaccine protect me?**

Different vaccines have different levels of effectiveness, but all approved vaccines have been protective against serious COVID-19 illness, hospitalization, and death. The efficacy of COVID-19 vaccines is determined through clinical trials, and post-trial effectiveness is measured through review of real-world data in vaccinated populations.

While the effectiveness of some COVID-19 vaccines early on was more than 90% against the circulating strains, the effectiveness wanes over time, with studies showing a decrease in antibodies around 5 to 6 months after the last dose. Many vaccines have shown decreased or limited effectiveness against infection with the Omicron variant, while remaining protective against severe disease and death. Studies indicate that a booster dose increases the level of protective antibodies against SARS CoV-2. Based on these studies, some countries have approved booster doses at 5 to 6 months after the completion of the primary series.

Getting to a point worldwide where most people are vaccinated will help prevent the development of additional variants, some of which could have properties that make vaccines less effective or ineffective. This is why it is important for everyone that can be vaccinated to do so as soon as possible.

**Does taking the vaccine guarantee someone is no longer able to transmit the virus?**

While in general vaccines may reduce the transmission of illness, the protective effect is never 100%, just as the vaccines are not 100% protective against symptomatic disease. Studies from the [U.S. CDC](https://www.cdc.gov), as well as other entities, have shown that COVID-19 can be spread by vaccinated individuals, particularly within households where a family member is infected. As a result, vaccinated people living in areas of high community spread should continue other important measures to prevent the spread of COVID-19, including mask wearing in indoor public spaces, social distancing, and avoiding crowded settings.
Who should get a COVID-19 vaccine booster?

A number of countries are considering or recommending COVID-19 vaccine booster shots to their populations, particularly those who fall into higher risk categories. (Booster doses are considered separate from additional, third doses of mRNA vaccine which are recommended for immunocompromised individuals as part of the full primary vaccination series. See FAQ on this below.) In the U.S., the CDC recommends that all individuals 12 and older who have completed a primary series get a booster dose. For those whose primary series was an mRNA vaccine, their booster should be at least 5 months after their last dose. For those who received the J&J vaccine, their booster should be at least 2 months later. The FDA and CDC have also said that people may receive a different booster shot than the primary series received. See here for U.S. CDC recommendations on COVID-19 vaccine boosters, and here for more detailed clinical considerations.

WHO supports broad access to vaccines and boosters, particularly for those at high risk for severe COVID-19 illness. WHO also advises that an additional dose of vaccine is recommended for immunocompromised individuals, as well as those who received an inactivated vaccine such as Sinovac, Sinopharm, or COVAXIN, or those who received the J&J vaccine. WHO guidance on COVID-19 vaccination is available here.

Staff should follow national health authority guidance in their location regarding boosters, including whether a booster dose is necessary to be considered fully vaccinated. If you do not fall into a group authorized for a booster dose of vaccine, or if you live in a location where boosters have not been authorized and have concerns, you should talk to your doctor before independently seeking out an additional vaccine dose. (Please note: At this time vaccine booster shots are not required in order to be considered fully vaccinated for the purposes of WBG vaccine requirements.

Booster shots should not be confused with the additional vaccine doses recommended for immunocompromised individuals.

If I am immunocompromised, should I get a third dose of COVID-19 vaccine?

The U.S. CDC recommends that moderately to severely immunocompromised people who received two doses of an mRNA vaccine get an additional (third) dose of mRNA COVID-19 vaccine at least 28 days after their initial 2 doses of Pfizer or Moderna. The additional dose should be the same vaccine as the initial series. This recommendation also includes children aged 5 to 11 who are moderately to severely immunocompromised.

For those who received the J&J vaccine and are moderately to severely immunocompromised, there currently is no recommendation from the U.S. CDC for an additional vaccine dose.

The CDC advises that after completing a primary series (whether 3 doses of mRNA or one dose of J&J), immunocompromised individuals may also receive a booster 6 months later if they finished an mRNA primary series or 2 months later if they had a J&J primary vaccination. See here for the CDC’s guidance on this.
This recommendation applies to those with weakened immune systems who have:

- Been receiving active cancer treatment for tumors or cancers of the blood
- Received an organ transplant and are taking medicine to suppress the immune system
- Received a stem cell transplant within the last two years or are taking medicine to suppress the immune system
- Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids or other drugs that may suppress the immune response

Why should immunocompromised people get a third COVID vaccine?

Having a compromised immune system puts you at higher risk of severe illness and death from COVID-19. Studies show that the initial vaccine doses are less effective for people with weakened immune systems, and they are also more likely to have a breakthrough infection than people in more normal health. Talk with your healthcare provider about your immunocompromised condition or its treatment to ensure the benefits outweigh the risks.

Do people who have already had COVID-19 need to get the vaccine or are they automatically protected?

Yes, they should be vaccinated, as prior illness alone does not provide the same level of protection. Vaccination is recommended by health authorities worldwide, even for those who have been previously infected. Studies indicate that immunity from infection does not protect against reinfection in the future, as this immunity decreases over time. There have been cases of reinfection in people who had a previous infection more than 90 days prior. A CDC study shows that individuals previously recovered from COVID-19 infection were five times as likely to be reinfected with COVID-19 as people who were vaccinated with two doses of Pfizer or Moderna. Additional studies have shown that vaccination after infection with COVID-19 (as well as breakthrough infection after vaccination) boosts immunity further and is expected provide protection for a longer period of time, particularly against severe illness, hospitalization, and death.

If I had COVID-19, can I receive the vaccine? And if so, how soon after?

Yes, you can receive the COVID-19 vaccine after you have recovered from your illness and have met the criteria for discontinuing isolation. The U.S. CDC notes that those who have been treated for COVID-19 with monoclonal antibodies or convalescent plasma should not receive a vaccine within 90 days of this treatment.
Can I choose which vaccine I get? What if I want to choose the vaccine that is most effective?

The best vaccine is the approved one that is soonest available to you. You may not have the opportunity to choose which vaccine you receive until there is more supply than demand. The most important thing is to receive an approved vaccine as soon as you are able. All of the approved vaccines are effective at preventing severe illness, hospitalization, and death, and the more quickly that people are vaccinated, the sooner that herd immunity will be reached, which will limit the spread of the virus.

Can the vaccine cause me to test positive for COVID-19?

No, the vaccine will not cause you to test positive for active infection with COVID-19. However, an antibody test may be positive because this tests for whether your body has produced antibodies to the virus, which help protect against the virus.

Mixing Vaccine Types: Is it safe? Can I get more than one type if the first one I get is not WHO approved?

While data on the safety and effectiveness of mixing different vaccine types remain limited, some studies do show that this can be a safe and effective approach. The CDC has endorsed this approach for those seeking boosters, saying that people eligible for boosters can select a different vaccine than the one they received for their primary series. (See a study supporting this approach here.) Other studies from the U.K., Germany, and Spain have shown that immunization with AstraZeneca and Pfizer (receiving either the AstraZeneca as first dose or the Pfizer as first dose, and then vice versa for the second dose) is as effective as two doses of either vaccine.

In the U.S., the following guidance applies:

mRNA vaccines: The U.S. CDC says that all doses of the primary series should be completed with the same product. However, if the same vaccine is not available, a second dose of a different mRNA vaccine may be given 28 days after the initial dose.

Vaccines approved by WHO: Those who have received a full series of COVID-19 vaccination by a WHO approved vaccine do not need any additional vaccination with a U.S. FDA approved vaccine, according the U.S. CDC. Those who have started, but NOT received a full series of COVID-19 vaccination by a WHO approved vaccine may be offered a U.S. FDA approved vaccine no sooner than 28 days after the last vaccine dose received.

Vaccines not approved by WHO: Those who have received a partial or full series of COVID-19 vaccination with a non-WHO approved vaccine may be offered a U.S. FDA approved vaccine, but no sooner than 28 days after the last vaccine dose received, according to the U.S. CDC.

Outside the U.S.:

Decisions on mixing and matching vaccine types should be guided by emerging evidence in support of this approach, in consultation with your doctor, following WHO and local health
authority guidance. The WHO does advise that in situations where a second dose of AstraZeneca is not available, a second dose of Pfizer or Moderna can be used.

**What can I safely do after being fully vaccinated?**

The safety of specific activities depends not only on vaccination status, but also the current status of community spread of the virus. Since vaccinated individuals can still become infected and spread the virus to others, in areas of high transmission, those who are vaccinated should follow sound public health practices of avoiding crowded areas (indoors or outdoors) and wearing a high-quality mask when indoors in public spaces.

**What this Means for Travel:**

- Within the U.S., the CDC advises that people should delay travel until they are up-to-date with their vaccines (including receiving booster doses if eligible). Those who are not up-to-date with their vaccines and who travel should get tested before travel and 3 to 5 days after travel, and should quarantine for 5 days after arrival.

- International travel poses additional risks. To travel to the U.S., international travelers have to be fully vaccinated with and FDA/WHO approved vaccine (or show documentation of recovery from COVID-19 in the last 3 months), and must be tested for COVID-19 within 1 day of their flight, and should still get tested 3 to 5 days after arrival, but they do not need to self-quarantine. They should also continue to follow all safety precautions during travel.

**mRNA Vaccines: Information and Safety**

This type of vaccine introduces a piece of mRNA (the genetic material that instructs cells to build specific proteins) into the body's cells. The mRNA instructs cells to make a protein which matches the structure of the spike protein found on the SARS-CoV2 virus, which is then displayed on the cell surface. The body's immune system recognizes this protein as foreign and builds antibodies against it. These antibodies will fight against any future infection with the virus. This is a new type of vaccine technology that can be produced more quickly than standard vaccines.

The Pfizer and Moderna mRNA vaccines have been approved by the WHO and other Stringent Regulatory Authorities based on their strong safety and efficacy profiles in clinical trials. Both these vaccines have received full approval from the U.S. FDA. In addition, safety monitoring continues as millions of people have already received the vaccine, and there have been no safety signals that indicate that the risk of vaccination is greater than the benefit. See here for the U.S. CDC’s information on adverse events.

You can read more here from WHO about how vaccines work. For a short explanation on how mRNA vaccines work, watch the video in this article.

**Questions about Allergic Reactions**

A relatively small number of severe allergic reactions (anaphylaxis) to the Pfizer and Moderna mRNA vaccines (among the millions who have received it) have been reported. While these
reactions are very rare in terms of incidence per million doses, those who have a prior history of immediate allergic reaction to any vaccination, injectable therapy for another disease, or vaccine component (including polyethylene glycol, which is present in the mRNA vaccines) should discuss with their doctor whether it is recommended to receive the mRNA vaccine. You can find information on the ingredients of the mRNA vaccines here: Pfizer, Moderna.

For those who have never had an allergic reaction to a vaccine and are not allergic to one of the ingredients in the mRNA vaccines, there is no contraindication to receiving an mRNA vaccine for reasons of allergy. For more information, see the U.S. CDC information on COVID-19 vaccines for people with allergies.

Questions about Safety for Adolescents and Young Adults

In the U.S., the CDC has noted a rare but increased rate of myocarditis and pericarditis (inflammation of the heart muscle or the tissues around the heart) among adolescent and young adult mRNA vaccine recipients, predominantly among males aged 16 and older, than would be expected normally in the population. This has been noted more often after the second dose than the first dose. While some of these cases require hospitalization and monitoring, the majority were mild and recover fully. The CDC continues to investigate these cases and monitor for any potential long-term effects. Myocarditis and pericarditis are conditions that can also occur with viral illness, including COVID-19 infection. The CDC emphasizes that the benefits of COVID-19 vaccination for this age group far outweigh the risks.

No cases of myocarditis or pericarditis were reported in the Pfizer vaccine trial for children aged 5 to 11.

AstraZeneca Vaccine: Information and Safety

The AstraZeneca vaccine is a viral vector vaccine using an inactivated adenovirus (a type of cold virus) to deliver a piece of DNA that codes for the spike protein characteristic of SARS CoV-2. It instructs the body's cells to create the spike protein and display it on the cell surface. This piece of DNA does not integrate into the body's DNA. The body's immune system identifies this spike protein foreign and creates antibodies against it that protect the recipient against SARS CoV-2. (For more information on how these vaccines work, read U.S. CDC information here, and a more detailed explanation from the New York Times vaccine tracker page.)

Questions about Safety

The AstraZeneca vaccine has been monitored by the European Medicines Agency (EMA) following rare reports of unusual blood clotting incidents in some people who received the vaccine. The WHO, along with the European Medicines Agency (EMA), determined that there is a plausible, but rare, link between the vaccine and unusual blood clots with low platelets. However, because these events are so rare weighed against the benefits of the vaccine, the WHO and EMA have recommended its continued use. The latest information from the EMA on the AstraZeneca vaccine can be found here.

Those who receive the vaccine should be aware of signs and symptoms for which they should seek urgent medical attention: shortness of breath, chest pain, leg swelling, persistent
abdominal pain, neurological symptoms such as severe persistent headaches or blurred vision, persistent bleeding, or tiny blood spots under the skin beyond the site of injection. In the cases investigated by the EMA and WHO, these blood clots occurred in the brain and the abdomen between 4 and 16 days after receiving the vaccine. Most cases were in women under 60 years of age. Reference the EMA’s safety update published on October 6, 2021.

It is important to note that infection with COVID-19 also carries a risk for blood clots (one meta-analysis found a rate of 7.8% risk of pulmonary embolism in COVID-19 patients) and the risks associated with COVID-19 infection can be severe and include death. Therefore, vaccination against COVID-19 remains the best way to protect oneself.

In addition, the AstraZeneca vaccine may have increased risk of Guillain-Barré Syndrome (GBS) following vaccination. GBS is a rare immune system disorder that results in muscle weakness, pain or numbness, and, in more severe cases, paralysis. GBS could result from different causes, including infections, and occurs more frequently in males and persons over 50 years old. Cases may occur coincidentally following vaccination. For example, rare cases of GBS have been observed following seasonal influenza vaccines and vaccines to protect against shingles, but it is not known if the vaccines cause GBS. The WHO Global Advisory Committee on Vaccine Safety (GACVS) emphasizes that the benefits of the vaccine continue to outweigh the risks.

Questions about Efficacy

In clinical trials, the AstraZeneca vaccine showed good efficacy against the SARS CoV-2 virus. However, when the Beta/B.1.35 variant began circulating in South Africa and other locations, data reviewed in South Africa showed that this vaccine was not effective in protecting against mild to moderate disease. Subsequently, AstraZeneca began a trial in June 2021 of an adjusted vaccine to be more protective against Beta, which could potentially be a model for future vaccines targeting variants with similar mutations. The Africa CDC says the use of the AstraZeneca vaccine should continue.

In locations where the AstraZeneca vaccine is the only vaccine available, global public health authorities advise people to receive this vaccine because of the good protection against serious illness or death. For further information from WHO on this vaccine, please check here.

Johnson and Johnson: Information and Safety

The Johnson & Johnson vaccine is a viral vector vaccine using an inactivated adenovirus (a type of cold virus) to deliver a piece of DNA that codes for the spike protein characteristic of SARS CoV-2. It instructs the body's cells to create the spike protein and display it on the cell surface. This piece of DNA does not integrate into the body's DNA. The body's immune system identifies this spike protein foreign and creates antibodies against it that protect the recipient against SARS CoV-2. (For more information on how these vaccines work, read U.S. CDC information here, and a more detailed explanation from the New York Times vaccine tracker page here.)

Questions about Safety

In the U.S. there have been a very small number of people who received the J&J vaccine who developed a rare kind of blood clot along with low platelets (platelets are a part of the blood
that causes clots). This rare condition is much like events investigated in Europe in relation to the AstraZeneca vaccine. Scientists believe that these blood clots in the brain or abdomen along with low platelets is an immune-mediated phenomenon similar to heparin-induced and auto-immune thrombocytopenia syndromes. Most of the cases identified in the U.S. were in women under 50 and occurred between 6 and 13 days after vaccination.

**U.S. regulatory authorities** determined that while these events are likely tied to the vaccine, the benefits of the vaccine outweigh the risks because of the very low incidence among those that received it (15 cases out of approximately 8 million vaccinated, or a rate of 7 in 1 million among women under 50). The pause on the vaccine which was in place during the investigation flagged to medical providers that this condition requires a different type of treatment than usually used to treat blood clots or low platelets. European and South African regulatory authorities are also continuing to use the vaccine.

Those who receive the vaccine should be aware of signs and symptoms in the 2 weeks after vaccination for which they should seek urgent medical attention, and tell their doctor they have received the vaccine: shortness of breath, chest pain, leg swelling, persistent abdominal pain, neurological symptoms such as severe persistent headaches or blurred vision, persistent bleeding, or tiny blood spots under the skin beyond the site of injection. (Anyone with these signs and symptoms anytime should seek urgent medical care.)

It is important to note that infection with COVID-19 also carries a risk for blood clots ([one meta-analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905131/) found a rate of 7.8% risk of pulmonary embolism in COVID-19 patients) and the risks associated with COVID-19 infection can be severe and include death. Therefore, vaccination against COVID-19 remains the best way to protect oneself.

In addition, the U.S. FDA has warned that the J&J vaccine may have increased risk of Guillain-Barré Syndrome (GBS) within 42 days of vaccination. GBS is a rare immune system disorder that results in muscle weakness, pain or numbness, and, in more severe cases, paralysis. GBS could result from different causes, including infections, and occurs more frequently in males and persons over 50 years old. Cases may occur coincidentally following vaccination. For example, rare cases of GBS have been observed following seasonal influenza vaccines and vaccines to protect against shingles, but it is not known if the vaccines cause GBS. The U.S. Advisory Committee on Immunization Practices (ACIP), as well as the WHO Global Advisory Committee on Vaccine Safety (GACVS) emphasize that the benefits of the vaccine continue to outweigh the risks.

See here for the [U.S. CDC’s information on adverse events](https://www.cdc.gov/vaccines/acip/index.html).

### Face Masks

**When should I use a face mask and which type?**

Masks are a key tool to [prevent the transmission of the SARS-CoV-2 virus](https://www.cdc.gov/coronavirus/2019-ncov/index.html) that causes COVID-19. They should be worn in situations where there may be a high risk of viral transmission, where recommended or required by local or national health authorities, or to protect oneself and one’s family members who are at high risk for severe COVID-19 illness. In areas of high community spread, masks are an important tool in situations of close contact,
closed spaces, and/or crowded places. They are also important in preventing transmission from people who are infected with COVID-19 but have no symptoms of illness.

Protection provided by a mask depends on both filtration and fit. If you are required/choose to wear a mask, wear the highest quality mask available to you and make sure it fits well around your face without any gaps. The best choice is an N95, KN95, or KF94 respirator mask (which has high filtration) that fits tightly around the mouth and nose. Surgical type masks provide better filtration than a cloth mask but may not provide a close fit. If possible, a cloth mask can be work over a surgical type mask to improve the fit around the face. Cloth masks alone should only be used if higher quality disposable masks/respirators are not available.

**Tips on Fit:**

To be effective, a mask must be worn over the mouth and nose.

If you have a mask with a nose wire, mold the wire to your nose bridge to close gaps.

Improve the fit of a disposable mask and eliminate the side gap by knotting the ear loops near the mask and tucking in the side of the mask for a close fit.

Two ways to check for fit:

- Exhale while feeling for airflow out the sides, top, and bottom of the mask with your hands.
- When you inhale, the mask should collapse toward your face, indicating no air being pulled in through the edges of the mask.

**Tips on Filtration:**

A mask should be at least 2 layers thick

- Respirator masks (designated as N95, PN95, or KF94) provide the highest level of filtration.
- Disposable surgical type masks are often made with 3-5 layers of fused material and provide the next best level of filtration – but may not offer a tight fit without adjustments.
- Cloth masks alone provide inadequate filtration and may be paired with a disposable mask to improve filtration. They should only be used if higher quality disposable masks/respirators such as KN95 or KF94 are not available. Cloth masks should be made with at least 2 layers of tightly woven breathable material. Check this by seeing if the fabric blocks light when held up to a bright light.

When using a face mask of any kind, it is essential to also use other measures to prevent spread of disease, avoiding the "3 Cs": 
• **Close contact** with others (stay at least 2 meters/6 feet away from others who are not in your household),

• Crowded places, and

• **Closed spaces** with poor ventilation.

Also remember to avoid touching your face and wash your hands frequently with soap and water.

Further information can be found below:

- [WHO: Novel Coronavirus (COVID-19) advice for the public: When and how to use masks](#)
- [CDC: Types of Masks and Respirators](#)

**Will mask wearing be required while in WBG buildings/offices?**

Yes, for all entrants to WBG HQ buildings, masks will be required in all common areas and meetings (except for those addressing an audience). Masks will be optional at workstations (in Service Center locations staff can choose to maintain wearing a mask as their preference when staff regularly come into close contact with others), and masks can be removed in the cafeterias when seated to eat.

Although local guidance on masking and social distancing has begun to relax for public places in the Washington, DC area, wearing a mask is still considered an essential part of our safe return to office at this time. **When masks are no longer mandated**, staff who wish to continue wearing masks should do so without pressure to remove them and should not be pressured to partake in activities in which they feel unsafe (i.e., meetings or gatherings in enclosed spaces). **Above all, those who have vulnerabilities or health concerns themselves or in their family should feel empowered to protect their health and the health of their family members by maintaining mitigation measures, to include home-based work.**

In **Country Offices**, staff who are returning to the office are also required to wear masks as outlined above. CO staff should also follow other local health and safety requirements.

**Finding a Healthcare Provider/COVID-19 Testing**

**Washington, DC, Area**

**Finding a Healthcare Provider**

1. Contact Teladoc (a telehealth provider) to get guidance on what you should do if you are sick (Aetna MIP). Information on Teladoc can be found at [Teladoc.com/Aetna](#). You can also download the Teladoc app.

2. You can also consider the following healthcare providers in the Washington, DC, Virginia, or Maryland areas. **Please call before arrival:**

   - [MedStar onsite WBG clinic](#)
MedStar urgent care/prompt care (DC and Maryland) – see MedStar locations
(select specifically for MedStar prompt care/urgent care)

GW Medical Faculty Associates (DC) – Immediate and Primary Care

Virginia Hospital Center in Arlington

INOVA Hospitals located throughout Fairfax County: Fairfax, Alexandria, and Fair Oaks as well as INOVA urgent care centers

COVID-19 Testing

For information on testing in DC, visit: https://coronavirus.dc.gov/testing.

For testing information in Maryland, visit: https://coronavirus.maryland.gov/pages/symptoms-testing.


Staff based in the U.S. can order 4 free at home COVID-19 rapid antigen tests provided by the U.S. Government: https://www.covidtests.gov/.

The CDC has a coronavirus self-checker tool which can help you make decisions (scroll to the bottom of the linked page). This tool is only intended for use by people currently in the United States.

Remember, in an emergency, first dial 911.

If you are tested for COVID-19 and receive a positive result, please notify HSD. If you have had contact with other staff members in the days before your diagnosis or onset of symptoms, please notify HSD by calling the WBG Emergency Line (+1 202-458-8888).

Country Office Location

Finding a Healthcare Provider

Please contact the Medical Emergency Response Coordinator (MERC) in your home country if you need urgent medical care. MERC contact details can be found in the country-specific information on the WBG Travel Advisory page.

If you have mild symptoms and need support finding a healthcare provider in your location, call the COVID-19 Global 24-hour Helpline (+1 202-458-8300).

If you are having a medical emergency, please contact the local emergency number in your location. Then, if additional emergency support is needed, contact the WBG Emergency Line (+1 202-458-8888).
COVID-19 Testing

For those living outside the U.S., in general, testing is under the control of local health authorities and may require a doctor's referral. Individuals should consult with their doctor in that location. As testing needs to be conducted as part of a local medical support strategy, COs are encouraged to coordinate with UN Country Teams.

If you are tested for COVID-19 and receive a positive result, please notify HSD. If you have had contact with other staff members in the days before your diagnosis or onset of symptoms, please notify HSD by calling the WBG Emergency Line (+1 202-458-8888).

I am Sick/My Dependent is Sick

What should I do if I have COVID-19?

Stay home and away from others. Your actions make a difference in limiting the spread of illness. Get rest and stay hydrated. Talk to your doctor to discuss your symptoms and to see whether you should be tested or need specific treatment.

Use good hygiene to prevent spreading your illness to others. Isolate yourself from other members of your household to the degree possible, sleeping in a separate bedroom and using a separate bathroom if available. Wear a mask around other household members and maintain at least a 2 meter/6-foot distance. Have your household members wear a mask any time they may need to be around you as well. Limit the time you spend in any common areas or around others in your home, even when maintaining physical distance and masking. Clean any high touch surfaces frequently.

If you or any household member that is ill has severe symptoms of illness, including emergency warning signs for COVID-19 such as trouble breathing, persistent pain or pressure in your chest, bluish lips or face, or new confusion or difficulty being woken, seek emergency medical care right away.

If symptoms of illness are not severe, but you need to seek medical care:

- Contact your healthcare provider by phone.
- If you need a healthcare provider, see "Finding a Healthcare Provider / COVID-19 Testing."
- If you must go out to receive medical care, wear a mask.
- If you test positive for COVID-19, or if your doctor diagnoses you clinically with COVID-19, notify HSD.
- If you have had contact with other staff members in the days before your diagnosis or onset of symptoms, please notify HSD by calling the WBG Emergency Line (+1 202-458-8888).
- In addition, please see the CDC's guidance here.
When can I be around others or return to the office after being diagnosed or ill with COVID-19?

Staff who have been ill with COVID-19 should not return to the workplace for a minimum of 10 days after their symptoms began or 10 days after their positive test (if asymptomatic).

Aside from workplace entry, staff should follow their doctor’s guidance for ending isolation after COVID-19 illness, in line with their national recommendations. In the absence of national guidelines, the WHO recommends that those with symptoms stay isolated for a minimum of 10 days after the first day they developed symptoms, plus another 3 days after the end of symptoms (no fever and no respiratory symptoms). For those without symptoms, they should stay isolated for 10 days after testing positive.

In the U.S., the CDC recently updated its guidance to shorten the isolation time for individuals infected with COVID-19 to 5 days for those who are asymptomatic or whose symptoms are resolving (without fever for 24 hours), followed by 5 days of wearing a mask around others (so wearing a mask for a total of 10 days after onset of illness or positive test). Those who have access to testing at the end the 5-day isolation period should use an antigen test and be fever free for 24 hours when testing. While staff may follow these guidelines in general regarding their isolation, for the workplace the 10-day exclusion remains in place. The reason for this is that studies indicate that 31% of infected individuals remain infectious 5 days after symptom onset or a positive test.

*If you are immunocompromised, confirm with your doctor when it is safe to be around others.

Reminder: According to the U.S. CDC, any unvaccinated, not fully vaccinated, or vaccinated and eligible for a booster but not yet boosted (i.e. more than 2 months after a J&J vaccine or 6 months after an mRNA vaccine) individual who has been in contact with someone diagnosed with COVID-19 should quarantine for at least 5 days after the last contact with the infected individual and get tested at least 5 days after exposure. If testing negative, wear a high quality mask in public for an additional 5 days. If testing positive, follow isolation guidelines. Fully vaccinated and boosted individuals do not need to quarantine if they have no symptoms, according to the U.S. CDC, but should wear a mask for 10 days after the exposure and get tested at least 5 days after last exposure. At any time, if you develop symptoms, you should isolate yourself and be tested for COVID-19.

I continue to have symptoms of illness, even though I’ve recovered from the acute phase of COVID-19. What can I expect and what resources are available to support me?

Some people who are no longer in the acute phase of COVID-19 illness continue to experience symptoms such as fatigue, fevers, cough, headaches, brain fog (problems with memory or focus), heart or vascular problems, or other symptoms. This "long-term COVID" is not yet well defined and it is unknown how many of those who have been diagnosed with COVID-19 continue to experience symptoms and face ongoing recovery. You should discuss these symptoms with your doctor and see what treatment or steps may be recommended. You should also take the time you need to recover, and not try to push yourself beyond your limits.
I am not Sick

What should I do if I have had close contact with a confirmed or probable COVID-19 case?

If you have been in close contact* with someone confirmed to have COVID-19, or who was declared a probable case and you are unvaccinated or not fully vaccinated (and boosted if eligible), according to the CDC, you should quarantine (stay at home) and avoid contact with others for a period of at least 5 days from the last known contact with the infected person, get tested at least 5 days after last exposure, and wear a mask for an additional 5 days if your test result is negative (if your result is positive, then you should isolate). If you are vaccinated and boosted if eligible, you do not need to quarantine if you have no symptoms. However, you should wear a mask for 10 days after last exposure and get tested at least 5 days after last exposure. If testing positive, then you should isolate.

In locations outside the U.S., you should follow local quarantine guidance. The European CDC also has shortened quarantine periods for extreme pressure situations with high caseloads. In the absence of national guidelines, staff should follow WHO recommendations.

If you develop symptoms at any time, you should isolate yourself and be tested for COVID-19. If you develop symptoms or test positive for COVID-19, contact HSD via email at travelhealth@worldbank.org. Your confidentiality will be respected.

If caring for someone who is sick with COVID-19, follow instructions for minimizing your exposure as outlined by the U.S. CDC.

*While data to precisely define "close contact" is limited, the U.S. CDC defines it as being within 2 meters/6 feet of an infected individual for 15 cumulative minutes over a 24 hour period (this may include multiple short contacts that add up to 15 minutes). More recent information since the prevalence of the Omicron variant indicate that a much shorter period of time and even fleeting contact could result in viral spread. Talk to your healthcare provider if you have questions about potential contact with a person who has COVID-19.

About COVID-19

How does COVID-19 spread?

COVID-19 spreads from person-to-person through respiratory particles that are exhaled when an infected person coughs, sneezes, talks, sings, or breathes. This happens most directly when someone is in close contact with an infected person (within 2 meters/6 feet). But it may happen at further distances with particles that are airborne, particularly if you are in a poorly ventilated space, among crowds, and not wearing a face mask. In addition, the Omicron variant is highly transmissible and may need only very brief interaction to be passed from one person to another. Please see WHO and CDC information on how COVID-19 spreads.

The virus can be spread by people that have NO symptoms. In a study published by JAMA (The Journal of the American Medical Association), over 50% of transmission of COVID-19 may be from individuals who are asymptomatic (either pre-symptomatic or who never develop symptoms).
The virus may spread by touching surfaces where respiratory droplets from infected people have landed, but this is more likely to happen in locations such as medical facilities or when taking care of a COVID-19 patient at home. If you touch a surface and then touch your nose, mouth or eyes without washing your hands, you may infect yourself. Do not touch your face, and wash your hands thoroughly for 20 seconds with soap and water after you have been in a public place or if you have been around someone who is sick.

Since COVID-19 can be spread by people who have no symptoms and other variants spread more easily than the original SARS CoV-2 strain, wear a mask whenever you are in close contact with others or in crowded conditions, even if you are vaccinated.

The best protection against any transmission of SARS CoV-2 is getting vaccinated when possible, proper distancing of at least 2 meters/6 feet from others who are not part of your household, wearing a mask when leaving home, and following these guidelines:

- Avoid the "3 Cs": crowded places, close contact settings, confined and enclosed spaces such as bars, restaurants, places of worship, gyms, waiting rooms, etc.
- Outdoors is better than indoors.
- Fresh air/open windows are safer than recirculated air.
- Proper filtration in ventilation systems is important.
- In indoor environments, spacing, number of people, time spent indoors, and type of activities can affect the risk level (i.e., gyms where people are breathing heavily are riskier than an office where proper distancing is maintained).

**What are the symptoms?**

- Fever (38.0 C/100.4 F or higher) or chills
- Cough
- Shortness of breath or difficulty breathing
- Fatigue
- Muscle or body aches
- Headache
- New loss of taste or smell
- Sore throat
- Congestion or runny nose
- Nausea or vomiting
- Diarrhea

Symptoms may be mild to severe and can appear from 1 to 14 days after exposure. If you or anyone you know experiences any of the following signs or symptoms while infected with
COVID-19, seek emergency medical care right away: trouble breathing, persistent chest pressure or pain, new confusion, inability to stay awake, bluish lips or face.

How do I prevent myself and others from becoming infected?

- Get vaccinated against COVID-19 when you have the opportunity. If local public health authorities recommend it, get a booster dose.
- In areas with high community spread, wear a mask in indoor settings when away from home and avoid crowded areas, close contact settings, and confined or enclosed spaces with poor air circulation. Stay physically distanced from others who are not part of your household, particularly if you do not know their vaccination status. Do not host or participate in any large gatherings. Wash your hands frequently with soap and water for 20 seconds, especially when returning from any public setting, before eating, and before touching your mouth, nose, or eyes. If no soap is available use an alcohol-based hand sanitizer.
- When coughing and sneezing, do NOT remove your mask (if you are outside of your home).
- If you are exposed to someone known or suspected to have COVID-19, and are not fully vaccinated (and boosted, if eligible), you should quarantine for at least 5 days (according to your national health authority guidance) after the last known contact and, wear a mask around others for at least 10 days, and monitor your health for symptoms of COVID-19. This quarantine period should include limiting contact with other household members if possible. According to the U.S. CDC, If you are fully vaccinated (and boosted, if eligible), you do not need to quarantine unless you have symptoms, but should wear a mask around others for 10 days and get tested at least 5 days after last exposure.
- If you were in a situation with high risk of COVID-19 transmission (such as a large gathering), monitor yourself for 10-14 days to see if you develop symptoms and follow distancing and masking precautions. If the gathering you attended has confirmed COVID-19 cases, discuss with your doctor whether you were exposed and whether you need to quarantine for at least 5 days and be tested (depending on your vaccination status).

Practice prudent social distancing measures:

- Avoid visiting elderly or vulnerable people if you and they are not vaccinated.
- Have your children practice social distancing if they are too young to be vaccinated or if they are not vaccinated. They should maintain at least 2 meters/6 feet from other unvaccinated children, especially in indoor settings, and wear a mask if indoors or in outdoor areas where they cannot maintain a distance from others. Cases in children can be asymptomatic, and you may not know if your child or someone else’s child has COVID-19.
• If restaurants are open, do not dine indoors if you are not vaccinated, or if you live in an area with high community spread.

• Do not attend or host gatherings among unvaccinated individuals.

• In areas of high community spread, go shopping only for essential items. Visit the grocery store at off-peak periods or when it is quieter.

• Minimize use of public transportation if you can for those who are unvaccinated and where crowding is present.

**What if I have a chronic medical condition and may be at a higher risk for illness from COVID-19?**

Certain individuals are at higher risk of severe illness from COVID-19. Those who are at higher risk should get vaccinated against COVID-19 as soon as they are able. That includes older adults (risk increases with age) and those with certain medical conditions:

• Cancer;

• Cerebrovascular disease;

• Chronic kidney disease;

• Chronic liver disease (cirrhosis, non-alcoholic or alcoholic fatty liver disease; autoimmune hepatitis);

• Chronic lung diseases (including moderate to severe asthma and COPD, see the full list [here](#));

• Cystic fibrosis;

• Dementia or other neurological conditions;

• Diabetes (type 1 or 2);

• Disabilities (including people with any type of disability that makes it more difficult to do certain activities or interact with the work around them; people with ADHD, cerebral palsy, birth defects, intellectual or developmental disabilities, learning disabilities, spinal cord injuries, or Down syndrome);

• Heart conditions (such as heart failure, coronary artery disease, cardiomyopathies, or possibly high blood pressure);

• HIV infection;

• Immunocompromised state (weakened immune system, including primary immunodeficiency);

• Mental health conditions (mood disorders, including depression and schizophrenia spectrum disorders);
- Overweight (defined as a body mass index (BMI) of > 25kg/m² but < 30kg/m²), obesity (BMI ≥30 kg/m² but < 40 kg/m²), or severe obesity (BMI of ≥40kg/m²), with the risk of severe COVID-19 illness increasing sharply with elevated BMI;
- Physical inactivity (people who do little to no physical activity or exercise);
- Pregnancy;
- Sickle cell disease or thalassemia;
- Smoking, current or former;
- Solid organ or blood stem cell transplant;
- Stroke or cerebrovascular disease, which affects blood flow to the brain;
- Substance use disorders;
- Tuberculosis.

See the [CDC's detailed list here](https://www.cdc.gov/coronavirus/2019-ncov/your-risk-factors.html).

For those who are at higher risk, wear a mask when in high-risk situations, avoid crowds, and strictly follow other public health guidelines. Ensure that you have enough of any prescription and over the counter medications you regularly need. Stay in touch with your doctor to ensure that your underlying medical condition is closely monitored. If you get sick, do not delay in seeking medical care.

**How can I safely gather with my family or community for celebrations or other events?**

If planning celebrations and gatherings with family and friends, consider who will be part of the gathering and what their vaccination status and vulnerabilities may be. The safest option for gathering is where all individuals are vaccinated, and where precautions are taken to limit crowding, poor ventilation, and close contact in areas with high community spread. In these areas, wearing a mask in indoor settings is advised for those who are unvaccinated, and testing prior to gatherings can also be used to prevent potential spread of the virus. Children older than 2 who are still too young to be vaccinated should continue masking and distancing. Vaccinated parents of young unvaccinated children should also consider carefully in what situations they may want to use a mask because of the potential for breakthrough infection and asymptomatic spread. (See more details from the CDC about how to consider risks for families in undertaking certain activities, and [CDC guidance for planning gatherings](https://www.cdc.gov/coronavirus/2019-ncov/community/safely-gathering.html).)

If you or any participants in a gathering become ill with symptoms of COVID-19 after the gathering or are notified that you are a contact of someone that is infected with COVID-19, you should follow local guidelines for testing and isolation or quarantine.
Travel

Are there specific testing requirements before traveling?

Many countries require a negative COVID-19 test for entry. The U.S. requires that all passengers traveling from overseas show a negative viral test taken no more than 1 day before the flight, regardless of vaccination status. Vaccination is a requirement for U.S. entry as of November 8, 2021 for those who are not citizens/legal permanent residents, with rare exceptions. For the vaccines accepted for entry to the U.S., view the CDC list here. For those recently ill with COVID-19 (within the last 90 days), they must show documentation of recovery: a copy of previous positive viral test results and a letter from their healthcare provider or a public health official that states they have been cleared for travel or cleared to end isolation.

You should check the testing requirements before travel with the health authorities of the destination country or location. Here is one location where you can find international travel restrictions: IATA Travel Regulations Map.

Do I need to be vaccinated before traveling? What are the vaccine requirements for entry to other countries?

Each country sets its own entry requirements, including whether vaccination is required for entry. To see what measures are required for entry to a country, the International Air Transport Association (IATA) publishes a map with entry data. This should be verified prior to travel by checking with the authorities of the destination country.

The U.S. has vaccination entry requirements as of November 8, 2021 for all passengers arriving by air. Travelers are required to show proof of vaccination with a U.S. or WHO approved vaccine, and are required to have a negative viral test 1 day before departure. For the vaccines accepted for entry to the U.S., view the CDC list here. Staff should closely check the documentation requirements for entry. There are limited exceptions to the vaccination requirement (such as for those who are citizens of a country with limited COVID-19 vaccine availability). For more detail on these travel requirements, see the CDC guidance on international travel here. Staff may also follow this CDC travel assessment to determine whether they will be allowed entry.

For U.S. entry, those who are not fully vaccinated but are otherwise allowed entry must have a negative viral test taken no more than one day before the flight departure. For additional information on types of tests accepted or documentation of recent recovery from COVID-19, see the CDC guidance here.